2019 年第 10 期 第 14 卷

不同剂量川芎嗪治疗脊髓损伤的临床效果比较

Clinical effects of different doses of ligustrazine on spinal cord injury

作者：都芳涛方继峰李兴晶乔培柳李广义

英文作者：

单位：252600泰山医学院附属聊城市第二人民医院骨外科

英文单位：

关键词：脊髓损伤；川芎嗪；炎性反应；肿瘤坏死因子α；白细胞介素1β

英文关键词：

• 摘要：

• 【摘要】目的    探讨不同剂量川芎嗪治疗脊髓损伤的临床效果。方法    选取2017年1月至2018年5月泰山医学院附属聊城市第二人民医院收治的脊髓损伤非手术患者90例，应用随机数字表法分为对照组和观察组，各45例。对照组在常规治疗基础上给予川芎嗪120 mg静脉滴注，观察组在常规治疗基础上给予川芎嗪240 mg静脉滴注；比较2组患者治疗前后脑脊液中肿瘤坏死因子α（TNF-α）和白细胞介素1β（IL-1β）mRNA的表达以及Botsford评分和功能独立性评定量表(FIM)评分的变化。结果    治疗前，2组患者脑脊液中TNF-α与IL-1β的mRNA含量比较，差异均无统计学意义(均P>0.05)。治疗后，2组患者脑脊液中TNF-α与IL-1β的mRNA含量均低于治疗前，且观察组低于对照组［(0.12±0.04)ng/L比（0.29±0.08）ng/L、（0.110±0.012）ng/L比（0.280±0.070）ng/L］，差异均有统计学意义(均P<0.01)。治疗前，2组患者Botsford评分及FIM评分比较，差异均无统计学意义(均P>0.05)。治疗后，2组患者Botsford评分及FIM评分均高于治疗前，且观察组高于对照组［(24.2±4.8)分比（20.9±2.8）分，(111±11)分比（90±11）分］，差异均有统计学意义(均P<0.05)。结论    川芎嗪可能通过影响脑脊液中TNF-α与IL-1 mRNA表达来促进脊髓损伤的康复，高剂量效果更加显著。

• 【Abstract】Objective    To observe the clinical effects of different doses of ligustrazine on spinal cord injury. Methods    Ninety non-surgical patients with spinal cord injury admitted to the Second People′s Hospital of Liaocheng Taishan Medical College  from January 2017 to May 2018 were randomly divided into control group and observation group, with 45 cases in each group. The control group was given intravenous drip of ligustrazine 120 mg while the observation group was given intravenous drip of ligustrazine 240 mg on the basis of routine treatment. Expressions of tumor necrosis factor-α(TNF-α) and interleukin-1β（IL-1β） mRNA in cerebrospinal fluid, Botsford score and Functional Independence Measure(FIM) score were analyzed before and after treatment. Results    There were no significant differences of TNF-α and IL-1β mRNA contents in cerebrospinal fluid between groups before treatment(both P>0.05). After treatment, levels of TNF-α and IL-1β mRNA significantly decreased in both groups, and the levels in observation group were lower than those in control group［(0.12±0.04)ng/L vs （0.29±0.08）ng/L， （0.110±0.012）ng/L vs （0.280±0.070）ng/L］(all P<0.01). There were no significant differences of Botsford score and FIM score between groups before treatment(P>0.05). After treatment, Botsford score and FIM score were significantly improved and the scores in observation group were higher than those in control group［(24.2±4.8) vs (20.9±2.8), (111±11) vs (90±11)］(all P<0.05). Conclusions    Ligustrazine may promote the rehabilitation of spinal cord injury by affecting expressions of TNF-α and IL-1β in cerebrospinal fluid. The therapeutic effect of high dose ligustrazine is more remarkable.